癌症领域的精密医疗的共同研究及授权契约:2016年～2025年

"肿瘤精准医疗合作与许可交易" 报告提供了前所未有的途径，让我们能够全面了解全球领先生物製药公司签署的肿瘤精准医疗交易。

本报告详细介绍了2016年至2025年期间的肿瘤精准医疗交易，并深入分析了企业达成肿瘤精准医疗交易的方式和原因。这些交易通常包含多个要素，从合作研发到成果商业化。

本报告涵盖了合作、开发、研究和授权交易。

本报告包​​含自2016年以来宣布的879项肿瘤精准医疗交易的完整列表，并提供了交易方披露的实际肿瘤精准医疗合作交易的在线交易记录链接。此外，报告还记录了公司及其合作伙伴向美国证券交易委员会提交的合约文件（如有）。

本报告第一章介绍了精准医疗肿瘤学交易。

第一章是对报告的介绍。

第二章概述了自2016年以来肿瘤精准医疗交易的趋势。

第三章概述了自2016年以来具有代表性的肿瘤精准医疗交易。交易按交易金额排序。

第四章提供了在肿瘤精准医疗交易领域最活跃的25家公司的综合列表及其简要摘要，随后是肿瘤精准医疗交易的综合列表以及公开的合同文件。

第五章全面深入地回顾了自2016年1月以来已达成或宣布的肿瘤精准医疗交易，并提供了公开的合约文件。

第六章全面深入地回顾了自2016年1月以来已签署和宣布的精准医疗肿瘤学合作交易。本章以重点关注的特定肿瘤精准医疗技术类型进行组织。

本章也提供了大量图表和数据，显示了自2016年以来精准医疗肿瘤学交易的趋势和活动。

此外，我们还提供了一个全面的交易目录，按公司A-Z、交易类型和治疗目标进行组织。每个交易标题都透过网页连结连结到线上交易记录，并在可用时包含合约文件，方便在需要时轻鬆存取每个合约文件。

主要的优点

精准医疗肿瘤学合作与授权协议为读者提供以下主要优势：

• 了解自2016年以来的交易趋势
• 浏览精准医疗肿瘤学合作与授权协议。
• 基准分析 - 确定交易的市场价值
• 财务条款 - 一次性付款、里程碑付款、特许权使用费
• 公司 A-Z、交易类型和治疗领域分类的交易目录
• 主要交易价值
• 最活跃的交易撮合者
• 确定每笔交易的资产和交易条款
• 存取合约文件 - 深入了解交易结构
• 尽职调查 - 评估拟议交易条款是否适合您的合作伙伴
• 节省数百小时的研究时间

调查范围

• 精准医疗肿瘤学合作与许可协议研究旨在深入了解全球领先生物製药公司签署的精准医疗肿瘤学交易的趋势和交易结构。

精准医疗肿瘤学合作及许可交易包括：

• 生物製药产业的精准医疗肿瘤学交易趋势
• 製药和生技产业精准医疗肿瘤学交易记录目录
• 主要的精准医疗肿瘤学交易
• 最活跃的精准医疗肿瘤学许可交易方
• 精准医疗肿瘤学合作及许可交易提供全面的交易记录访问，包括可用的合约文件。

分析合约有助于进行以下方面的尽职调查：

• 授予或选择的具体权利是什么？
• 合约实际上授予合作公司什么？
• 授予了哪些独家经营权？
• 合约的付款结构是怎样的？
• 如何审计销售和付款？
• 合约期限是多久？
• 合约的关键条款是如何定义的？
• 知识产权如何处理与归属？
• 谁负责商业化？
• 谁负责开发、供应和製造？
• 如何管理保密和资讯揭露？
• 如何解决争议？
• 合约在什么情况下可以终止？
• 如果所有权发生变更会怎样？
• 双方同意了哪些分授权和分包条款？
• 公司坚持哪些样板条款？
• 哪些样板条款似乎因合作伙伴和交易类型而异？
• 公司主张哪个契约法管辖区？

目录

摘要整理

第1章 简介

第2章 肿瘤学的交易的精密医疗趋势

• 简介
• 癌症领域的精密医疗的多年的交易
• 最活跃的精密医疗交易
• 癌症领域的精密医疗交易，不同的交易型态
• 癌症领域的精密医疗交易，各领域
• 癌症领域的精密医疗交易，各业界
• 癌症领域的精密医疗交易条件

第3章 肿瘤学交易的精密医疗的先导

• 简介
• 主要的癌症领域的精密医疗交易，各金额

第4章 肿瘤学的交易厂商的最活跃的肿瘤精准医疗交易交易者

• 简介
• 癌症领域的最活跃的精密医疗交易厂商
• 最活跃的癌症领域的精密医疗交易企业简介

第5章 癌症领域的精密医疗交易名录

• 简介
• 癌症领域的精密医疗交易名录

第6章 癌症领域的精密医疗交易- 各技术类型

• 交易名录
• 交易名录- 癌症领域的精密医疗的交易，各企业
• 交易名录- 癌症领域的精密医疗的交易各交易类型
• 交易名录- 癌症领域的精密医疗的交易，各治疗领域
• 交易类型定义
• 关于调查公司
• 目前联盟
• 目前契约
• 最近的报告标题

Precision Medicine in Oncology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the precision medicine in oncology deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of precision medicine in oncology deals from 2016 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter precision medicine in oncology deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 879 precision medicine in oncology deals announced since 2016 including financial terms where available including links to online deal records of actual precision medicine in oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of precision medicine in oncology dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in precision medicine in oncology dealmaking since 2016.

Chapter 3 provides an overview of the leading precision medicine in oncology deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in precision medicine in oncology dealmaking with a brief summary followed by a comprehensive listing of precision medicine in oncology deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of precision medicine in oncology deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of precision medicine in oncology partnering deals signed and announced since Jan 2016. The chapter is organized by specific precision medicine in oncology technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in precision medicine in oncology deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Precision Medicine in Oncology Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse precision medicine in oncology collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Precision Medicine in Oncology Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of precision medicine in oncology trends and structure of deals entered into by leading biopharma companies worldwide.

Precision Medicine in Oncology Collaboration and Licensing Deals includes:

• Trends in precision medicine in oncology dealmaking in the biopharma industry
• Directory of precision medicine in oncology deal records covering pharmaceutical and biotechnology
• The leading precision medicine in oncology deals by value
• Most active precision medicine in oncology licensing dealmakers
• Precision Medicine in Oncology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in precision medicine in oncology dealmaking

• 2.1. Introduction
• 2.2. Precision medicine in oncology deals over the years
• 2.3. Most active precision medicine in oncology dealmakers
• 2.4. Precision medicine in oncology deals by deal type
• 2.5. Precision medicine in oncology deals by therapy area
• 2.6. Precision medicine in oncology deals by industry sector
• 2.7. Deal terms for precision medicine in oncology deals
  • 2.7.1 Precision medicine in oncology deals headline values
  • 2.7.2 Precision medicine in oncology deal upfront payments
  • 2.7.3 Precision medicine in oncology deal milestone payments
  • 2.7.4 Precision medicine in oncology royalty rates

Chapter 3 - Leading precision medicine in oncology deals

• 3.1. Introduction
• 3.2. Top precision medicine in oncology deals by value

Chapter 4 - Most active precision medicine in oncology dealmakers

• 4.1. Introduction
• 4.2. Most active precision medicine in oncology dealmakers
• 4.3. Most active precision medicine in oncology deals company profiles

Chapter 5 - Precision medicine in oncology contracts dealmaking directory

• 5.1. Introduction
• 5.2. Precision medicine in oncology contracts dealmaking directory

Chapter 6 - Precision medicine in oncology dealmaking by technology type

• Deal directory
• Deal directory - Precision medicine in oncology deals by company A-Z
• Deal directory - Precision medicine in oncology deals by deal type
• Deal directory - Precision medicine in oncology deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Precision medicine in oncology deals since 2016
• Figure 2: Active precision medicine in oncology dealmaking activity - 2016 - 2025
• Figure 3: Precision medicine in oncology deals by deal type since 2016
• Figure 4: Precision medicine in oncology deals by therapy area since 2016
• Figure 5: Precision medicine in oncology deals by industry sector since 2016
• Figure 6: Precision medicine in oncology deals with a headline value
• Figure 7: Precision medicine in oncology deals with an upfront value
• Figure 8: Precision medicine in oncology deals with a milestone value
• Figure 9: Precision medicine in oncology deals with a royalty rate value
• Figure 10: Top precision medicine in oncology deals by value since 2016
• Figure 11: Most active precision medicine in oncology dealmakers 2016 - 2025
• Figure 12: Precision medicine in oncology deals by technology type since 2016